{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:07:09Z","timestamp":1788887229450,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"DOI":"10.1007\/s41999-026-01604-w","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:15:50Z","timestamp":1788884150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma neuroimmune pathway signatures are associated with clinical impairment and lower MRI-derived hippocampal volume across the Alzheimer\u2019s disease continuum"],"prefix":"10.1007","author":[{"given":"Mubarak","family":"Alruwaili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhannad Faleh","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailah M.","family":"Almohaimeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0563-839X","authenticated-orcid":false,"given":"Saud S.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah","family":"Alruwais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Ali","family":"Elkordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Alshuhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"1604_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf413","author":"LL Raket","year":"2025","unstructured":"Raket LL, Pichet Binette A, Mattsson-Carlgren N, Janelidze S, Zetterberg H, Ashton NJ et al (2025) Estimating the time course of biomarker changes in Alzheimer\u2019s disease. Brain. https:\/\/doi.org\/10.1093\/brain\/awaf413","journal-title":"Brain"},{"issue":"1","key":"1604_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3233\/JAD-215724","volume":"87","author":"Y Liu","year":"2022","unstructured":"Liu Y, Han PR, Hu H, Wang ZT, Guo Y, Ou YN et al (2022) A multi-dimensional comparison of Alzheimer\u2019s disease neurodegenerative biomarkers. J Alzheimers Dis 87(1):197\u2013209","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"1604_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaneurol.2025.1100","volume":"82","author":"A Pichet Binette","year":"2025","unstructured":"Pichet Binette A, Smith R, Salvad\u00f3 G, Tideman P, Glans I, van Westen D et al (2025) Evaluation of the revised criteria for biological and clinical staging of Alzheimer disease. JAMA Neurol 82(7):666\u2013675","journal-title":"JAMA Neurol"},{"issue":"4","key":"1604_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H et al (2023) Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol 80(4):360\u2013369","journal-title":"JAMA Neurol"},{"issue":"1","key":"1604_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01459-y","volume":"16","author":"HE Dark","year":"2024","unstructured":"Dark HE, An Y, Duggan MR, Joynes C, Davatzikos C, Erus G et al (2024) Alzheimer\u2019s and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline. Alzheimers Res Ther 16(1):94","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1604_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034341","volume":"7","author":"D Johnstone","year":"2012","unstructured":"Johnstone D, Milward EA, Berretta R, Moscato P (2012) Multivariate protein signatures of pre-clinical Alzheimer\u2019s disease in the Alzheimer\u2019s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS ONE 7(4):e34341","journal-title":"PLoS ONE"},{"issue":"1","key":"1604_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/alz.13449","volume":"20","author":"DP Veitch","year":"2021","unstructured":"Veitch DP, Weiner MW, Miller M, Aisen PS, Ashford MA, Beckett LA et al (2021) The Alzheimer\u2019s disease neuroimaging initiative in the era of Alzheimer\u2019s disease treatment: a review of ADNI studies from 2021 to 2022. Alzheimers Dement 20(1):652\u2013694","journal-title":"Alzheimers Dement"},{"issue":"20","key":"1604_CR8","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1016\/j.cell.2023.08.037","volume":"186","author":"N Sun","year":"2023","unstructured":"Sun N, Victor MB, Park YP, Xiong X, Scannail AN, Leary N et al (2023) Human microglial state dynamics in Alzheimer\u2019s disease progression. Cell 186(20):4386\u2013403.e29","journal-title":"Cell"},{"issue":"4","key":"1604_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cell.2020.06.038","volume":"182","author":"WT Chen","year":"2020","unstructured":"Chen WT, Lu A, Craessaerts K, Pavie B, Sala Frigerio C, Corthout N et al (2020) Spatial transcriptomics and in situ sequencing to study Alzheimer\u2019s disease. Cell 182(4):976\u201391.e19","journal-title":"Cell"},{"issue":"7903","key":"1604_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41586-021-04369-3","volume":"603","author":"AC Yang","year":"2022","unstructured":"Yang AC, Vest RT, Kern F, Lee DP, Agam M, Maat CA et al (2022) A human brain vascular atlas reveals diverse mediators of Alzheimer\u2019s risk. Nature 603(7903):885\u2013892","journal-title":"Nature"},{"issue":"1","key":"1604_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12987-024-00580-2","volume":"21","author":"Y Ding","year":"2024","unstructured":"Ding Y, Palecek SP, Shusta EV (2024) iPSC-derived blood-brain barrier modeling reveals APOE isoform-dependent interactions with amyloid beta. Fluids Barriers CNS 21(1):79","journal-title":"Fluids Barriers CNS"},{"issue":"4","key":"1604_CR12","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1007\/s11357-024-01112-4","volume":"46","author":"R Casanova","year":"2024","unstructured":"Casanova R, Walker KA, Justice JN, Anderson A, Duggan MR, Cordon J et al (2024) Associations of plasma proteomics and age-related outcomes with brain age in a diverse cohort. Geroscience 46(4):3861\u20133873","journal-title":"Geroscience"},{"issue":"2","key":"1604_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055531","volume":"8","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Da X, Bhatt P, Wolk DA, Arnold SE, Shaw LM et al (2013) Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS ONE 8(2):e55531","journal-title":"PLoS ONE"},{"issue":"9","key":"1604_CR14","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.1002\/alz.14142","volume":"20","author":"MR Duggan","year":"2024","unstructured":"Duggan MR, Yang Z, Cui Y, Dark HE, Wen J, Erus G et al (2024) Proteomic analyses reveal plasma EFEMP1 and CXCL12 as biomarkers and determinants of neurodegeneration. Alzheimers Dement 20(9):6486\u20136505","journal-title":"Alzheimers Dement"},{"issue":"1-3","key":"1604_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF02815208","volume":"28","author":"PS Aisen","year":"1996","unstructured":"Aisen PS (1996) Inflammation and Alzheimer disease. Mol Chem Neuropathol 28(1\u20133):83\u201388","journal-title":"Mol Chem Neuropathol"},{"issue":"6286","key":"1604_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S et al (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352(6286):712\u2013716","journal-title":"Science"},{"issue":"11","key":"1604_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC, Alexopoulos H, Spaeth PJ (2020) Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 16(11):601\u2013617","journal-title":"Nat Rev Neurol"},{"key":"1604_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-pathol-031620-113409","volume":"16","author":"NE Propson","year":"2021","unstructured":"Propson NE, Gedam M, Zheng H (2021) Complement in neurologic disease. Annu Rev Pathol 16:277\u2013298","journal-title":"Annu Rev Pathol"},{"key":"1604_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413647","author":"A Shah","year":"2021","unstructured":"Shah A, Kishore U, Shastri A (2021) Complement system in Alzheimer\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222413647","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1604_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archgenpsychiatry.2010.78","volume":"67","author":"M Thambisetty","year":"2010","unstructured":"Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67(7):739\u2013748","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"1604_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028527","volume":"6","author":"M Thambisetty","year":"2011","unstructured":"Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y et al (2011) Plasma biomarkers of brain atrophy in Alzheimer\u2019s disease. PLoS ONE 6(12):e28527","journal-title":"PLoS ONE"},{"issue":"11","key":"1604_CR22","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1007\/s00415-008-0006-8","volume":"255","author":"M Thambisetty","year":"2008","unstructured":"Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A et al (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer\u2019s disease. J Neurol 255(11):1712\u20131720","journal-title":"J Neurol"},{"issue":"8","key":"1604_CR23","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.immuni.2023.06.016","volume":"56","author":"L Zhong","year":"2023","unstructured":"Zhong L, Sheng X, Wang W, Li Y, Zhuo R, Wang K et al (2023) TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Immunity 56(8):1794\u2013808.e8","journal-title":"Immunity"},{"issue":"7806","key":"1604_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A et al (2020) APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 581(7806):71\u201376","journal-title":"Nature"},{"issue":"6","key":"1604_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-021-00073-z","volume":"1","author":"A Montagne","year":"2021","unstructured":"Montagne A, Nikolakopoulou AM, Huuskonen MT, Sagare AP, Lawson EJ, Lazic D et al (2021) APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer\u2019s mice via cyclophilin A independently of amyloid-\u03b2. Nat Aging 1(6):506\u2013520","journal-title":"Nat Aging"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01604-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-026-01604-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01604-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:15:52Z","timestamp":1788884152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-026-01604-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":25,"alternative-id":["1604"],"URL":"https:\/\/doi.org\/10.1007\/s41999-026-01604-w","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted using ADNI data. The ADNI study is ethically approved and operated in accordance with the Declaration of Helsinki, 1964.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}